Hematology Allogeneic Stem Cell Transplantation: Expert Review and Commentary Dr. Mattias Stelljes, Dr. Thomas J. Nevill & Dr. Victor Lewis Conditioning for Allogeneic Hematopoietic Stem Cell: Strategies Compared Download 2 PowerPoint slides
Hematology Waldenström Macroglobulinemia: Expert Interview Dr. Laurie H Sehn — Length: 06:19 A Canadian Perspective on the Role of BTK Inhibitors in the Treatment of WM Watch Presentation
Hematology 64th American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Carolyn Owen — Length: 05:00 ALPINE Trial Demonstrates Superior Response of Second-Generation BTK Inhibitor in CLL/SLL Watch Presentation
Hematology 64th American Society of Hematology (ASH) Annual Meeting and Exposition December 10-13, 2022 — New Orleans, Louisiana ALPINE Head-to-head Trial, Second-generation BTK Inhibitor Shown to be More Effective and Safer in CLL Download 4 PowerPoint slides
Hematology 64th American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Dennis Kim — Length: 05:18 STAMP Inhibitor Broadens the Treatment Landscape in Chronic Myeloid Leukemia Watch Presentation
Hematology 64th American Society of Hematology (ASH) Annual Meeting and Exposition December 10-13, 2022 — New Orleans, Louisiana Novel Small Molecule Inhibitor Broadens the Treatment Landscape in Chronic Myeloid Leukemia Download 4 PowerPoint slides
Hematology 64th American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Laurie H. Sehn — Length: 05:00 New Data Shifts Risk-benefit of BTK Inhibitors in CLL/SLL Watch Presentation
Hematology 2022 European Hematology Association (EHA) Congress Dr. Carolyn Owen — Length: 05:14 Long-term ASPEN Data: Demonstrated Efficacy and Tolerability in Patients with Waldenström Macroglobulinemia Watch Presentation
Hematology American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Dr. Versha Banerji — Length: 04:15 Continued Benefit for First-line CLL Treatment: ELEVATE-TN 5-year Follow-up Watch Presentation
Hematology American Society of Clinical Oncology (ASCO) 2022 Annual Meeting June 3-7, 2022 — Chicago, Illinois ELEVATE-TN: At 5 Years, Progression-free Survival with High Tolerability Maintained in Treatment-naïve CLL Patients Download 4 PowerPoint slides
Hematology American Society of Clinical Oncology (ASCO) 2022 Annual Meeting June 3-7, 2022 — Chicago, Illinois ASPEN Study: Long-Term Clinical Advantages of a Newer BTK Inhibitor in Waldenström Macroglobulinemia Confirmed Download 6 PowerPoint slides
Hematology 63rd American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Christine I. Chen — Length: 08:52 Latest Data Reinforce ASPEN Study Results on BTK Specificity in WM Watch Presentation